Skip to main content
Clinical Trials/NCT06290921
NCT06290921CompletedNot Applicable

Ovulation Trigger with Less Than 3 Follicles in Stimulated In-vitro Fertilization (IVF) Cycles

Clinique Ovo1 site in 1 country405 target enrollmentStarted: February 22, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
405
Locations
1
Primary Endpoint
Clinical Pregnancy Rate

Study Overview

Brief Summary

Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists. Although poor responders tend to have sub-optimal fertility treatment outcomes, many of these patients wish to attempt at least one IVF cycle. Traditionally, IVF cycles producing less than 3 to 4 mature follicles (measuring at least 14 mm) have either been cancelled or converted to intra-uterine insemination (IUI) due to the low pregnancy rates associated with these cycles. The minimal number of follicles required to proceed with egg collection is based on clinical experience, having been determined by weighing the probability of implantation and pregnancy versus the risk of not obtaining quality oocytes or reaching embryo transfer when fewer mature follicles are present. This retrospective quality control study aims to compare pregnancy rates in IVF cycles producing 3 follicles measuring 14 mm and more on trigger day, versus 2 or fewer follicles.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 42 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Stimulated IVF cycle at clinique ovo
  • Patients with a maximum of 3 mature follicles (≥14mm) on the day of ovulation trigger

Exclusion Criteria

  • Cycle cancelation due to no follicles
  • History of recurrent implantation failure
  • Contraindication of ovulation induction medication

Outcomes

Primary Outcomes

Clinical Pregnancy Rate

Time Frame: 6 to 8 weeks after Frozen Embryo Transfer

clinical pregnancy is the presence of fetal heartbeat at the viability ultrasound

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Clinique Ovo
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials